SynAct post-hoc Phase 2b analysis backs Phase 3 path
SynAct Pharma AB says a post-hoc analysis of its Phase 2b ADVANCE study reinforces Phase 2b EXPAND results and supports Phase 3 development. FDA trial-design discussions are planned for Q4 2026.
Story updates
09:15:02 AM UTC
SquawkNews
SYNACT - Further Analysis of the Phase 2b ADVANCE Study Reinforces Phase 2b EXPAND Results and Supports Phase 3 Development - FDA Discussions on Trial Design Planned for Q4 2026
SynAct Pharma AB (publ) (“SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic approach known as “pro-resolution”, today announced results from a post-hoc analysis of the Phase 2b ADVANCE study evaluating resomelago…